Kyverna Therapeutics, Inc. (KYTX) SEC Filings & Earnings Calls

Clinical trial risks remain, including potential for results not to replicate in larger trials and need for additional capital.

“risks that the results from the Planned Phase 3 Study may not ultimately support FDA approval of efzofitimod in pulmonary sarcoidosis”

Clinical-stage biopharmaceutical company with no approved products

“The Company has incurred losses and negative cash flows from operations since inception. As of June 30, 2026, the Company had an accumulated deficit of $502.9 million.” · word for word

Need for substantial additional funding

“Unless and until it does, the Company will need to continue to raise additional capital.” · word for word

Shareholder class action and derivative lawsuits

“On December 9, 2024, a shareholder class action complaint was filed... The Company believes it has good and substantial defenses to the claims... but there is no guarantee that it will be successful in these efforts.”

Clinical-stage biotech with no approved products; regulatory and commercial risks.

“Net loss $38.3M; no product revenue.”

Dependence on successful BLA submission and FDA approval for SPS.

“Rolling BLA submission for SPS on track for Q4 2026; potential commercial launch in 2027.”

Revenue covenant risk starting Q2 2027

“Company will be subject to minimum revenue covenants beginning with the quarter ending June 30, 2027” · word for word

Milestone-dependent financing adds execution risk

“Term B and C Loans contingent on clinical and revenue milestones”

Pre-revenue clinical-stage company with no approved products

“The Company has incurred losses and negative cash flows from operations since inception. As of March 31, 2026, the Company had an accumulated deficit of $464.6 million.” · word for word

Litigation risk from securities class action and derivative lawsuits

“On December 9, 2024, a shareholder class action complaint was filed... The Amended Complaint alleges that the registration statement on Form S-1 filed in connection with the IPO and the prospectus contained therein contained material misstatements or omissions in violation of federal securities laws.”

High cash burn rate may require additional financing

“Net cash used in operating activities $41,597 (2026) vs $44,915 (2025). Unless and until it does, the Company will need to continue to raise additional capital.”

Debt covenant risk from term loan facility

“The Loan and Security Agreement contains customary affirmative and negative covenants... Beginning on the applicable cash covenant commencement date, but no later than February 28, 2027, the Company is required to maintain minimum unrestricted cash balances... The Loan Facility also includes minimum revenue covenants beginning in 2027.” · word for word

Clinical trial risk remains; Phase 3 gMG trial still enrolling; no approved therapies in SPS yet.

“Enrollment advances in Phase 3 trial in generalized myasthenia gravis (gMG).” · word for word

Nasdaq delisting risk

“If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock.” · word for word

Equity dilution risk

“Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.” · word for word

Regulatory risk; BLA submission and approval not guaranteed.

“BLA submission anticipated in 1H 2026; FDA review outcome uncertain.”

Clinical trial risk; Phase 3 gMG trial may fail to meet endpoints.

“Phase 3 gMG trial enrolling; positive interim data but final results pending.”

Clinical and regulatory risks: BLA submission and FDA approval not guaranteed; Phase 3 gMG trial enrollment and data readout subject to uncertainty.

“Forward-looking statements regarding BLA filing, launch readiness, and trial execution are inherently uncertain.”

Cash burn rate: clinical-stage company with no approved products; cash runway depends on trial timelines and regulatory outcomes.

“Cash runway into 2028 assumes successful execution of clinical and regulatory milestones.”

Intellectual property risk

“If we or our licensors fail to adequately protect this intellectual property, our business, results of operations and financial condition could be adversely affected.” · word for word

Clinical trial failure risk remains for SPS and gMG Phase 3; regulatory approval not guaranteed.

“Phase 2 data is interim; Phase 3 enrollment not yet started; BLA submission subject to FDA review.”

Cash runway into 2027 depends on successful execution and no major delays; loan facility adds debt obligation.

“Cash runway into 2027, but $150M loan facility adds interest and repayment obligations.”